Evidence map›Paper›PMID 36890657›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Immunomodulatory Microparticles Epigenetically Modulate T Cells and Systemically Ameliorate Autoimmune Arthritis.

David A McBride, Matthew D Kerr, Wade T Johnson, Anders Nguyen, Martina Zoccheddu, Mina Yao, Edward B Prideaux, Nicholas C Dorn, Wei Wang, Mattias N D Svensson and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. TScience immunology · 2025
    Article
  2. Article
  3. Vaccine therapy for rheumatoid arthritis: A step forward.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  4. Therapeutic delivery of CCL2 modulates immune response and restores host-microbe homeostasis.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

David A McBrideDepartment of Nanoengineering, University of California, La Jolla, San Diego, CA, 92093, USA.
Matthew D KerrDepartment of Nanoengineering, University of California, La Jolla, San Diego, CA, 92093, USA.
Wade T JohnsonDepartment of Nanoengineering, University of California, La Jolla, San Diego, CA, 92093, USA.
Anders NguyenDepartment of Rheumatology and Inflammation Research, Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Gothenburg, 41346, Sweden.
Martina ZocchedduDepartment of Medicine, Division of Rheumatology, Allergy and Immunology, University of California, La Jolla, San Diego, CA, 92093, USA.
Mina YaoDepartment of Chemistry and Biochemistry, University of California, La Jolla, San Diego, CA, 92093, USA.
Edward B PrideauxDepartment of Chemistry and Biochemistry, University of California, La Jolla, San Diego, CA, 92093, USA.
Nicholas C DornDepartment of Nanoengineering, University of California, La Jolla, San Diego, CA, 92093, USA.
Wei WangDepartment of Chemistry and Biochemistry, University of California, La Jolla, San Diego, CA, 92093, USA.
Mattias N D SvenssonDepartment of Rheumatology and Inflammation Research, Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Gothenburg, 41346, Sweden.
Nunzio BottiniDepartment of Medicine, Division of Rheumatology, Allergy and Immunology, University of California, La Jolla, San Diego, CA, 92093, USA.
Nisarg J ShahDepartment of Nanoengineering, University of California, La Jolla, San Diego, CA, 92093, USA.ORCID 0000-0003-1727-5732
University of California San Diego · USLa Jolla Institute for Immunology · USUniversity of Gothenburg · SE

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Identification of key regulators in rheumatoid arthritisR01AR065466 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, WANG, WEI · 2014 to 2024
$4.6M
Resource-based Center for the study of the joint microenvironment in rheumatology (Overall Application)P30AR073761 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHUNG, CHRISTINE B · 2018 to 2022
$3.9M
Rheumatic Diseases Research Training GrantT32AR064194 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GARY S FIRESTEIN, Monica Guma · 2013 to 2026
$3.8M
Role of PTPN2 in rheumatoid arthritisR01AI148073 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOTTINI, NUNZIO · 2019 to 2023
$2.7M
Cancer Researchers in Nanotechnology (CRIN)T32CA153915 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KUMMEL, ANDREW CLYDE, ZHANG, DONG-ER · 2017 to 2021
$994k
NovaSeq5000 High Throughput SequencerS10OD025052 · OD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SEUMOIS, GREGORY · 2018 to 2018
$832k
Microparticles Modulating Regulatory T cells in Periodontal DiseaseR03DE031009 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHAH, NISARG J. · 2021 to 2022
$286k
Engineered biomaterials modulating inflammatory T cells in rheumatic arthritisF31AR079921 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MCBRIDE, DAVID AMBROSE · 2021 to 2022
$79k
Biomaterial scaffold-assisted drug delivery to modulate acute graft-versus-host-diseaseF31HL164055 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KERR, MATTHEW DAVID · 2022 to 2022
$39k
NCATS NIH HHS UL1 TR001442NCI NIH HHS P30 CA023100NCI NIH HHS T32 CA153915NHLBI NIH HHS F31 HL164055NIAID NIH HHS R01 AI148073NIAMS NIH HHS F31 AR079921NIAMS NIH HHS P30 AR073761NIAMS NIH HHS R01 AR065466NIAMS NIH HHS T32 AR064194NIDCR NIH HHS R03 DE031009NIH HHS F31AR079921(D.A.M.)NIH HHS F31HL164055(M.D.K.)NIH HHS P30AR073761(N.B.)NIH HHS P30CA23100NIH HHS R01AI148073(N.B.)NIH HHS R03DE031009(N.J.S)NIH HHS S10 OD025052NIH HHS S10OD025052NIH HHS T32AR064194NIH HHS T32CA153915NIH HHS UL1TR001442
6 · The paper itself

Abstract

Disease modifying antirheumatic drugs (DMARDs) have improved the prognosis of autoimmune inflammatory arthritides but a large fraction of patients display partial or nonresponsiveness to front-line DMARDs. Here, an immunoregulatory approach based on sustained joint-localized release of all-trans retinoic acid (ATRA), which modulates local immune activation and enhances disease-protective T cells and leads to systemic disease control is reported. ATRA imprints a unique chromatin landscape in T cells, which is associated with an enhancement in the differentiation of naïve T cells into anti-inflammatory regulatory T cells (T

Indexed as

Antirheumatic AgentsArthritisAutoimmune DiseasesAnimalsInflammationMiceT-Lymphocytes, RegulatoryTretinoinAntirheumatic AgentsTretinoinimmune engineeringregulatory T cellsrheumatoid arthritis

Identifiers

PMID36890657
PMCPMC10104670
OpenAlexW4323652643

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.